Member Info for Matml74

“ Additionally, IFN themselves have recently shown promising therapeutic potential against COVID-19 with molecular mechanisms involving both anti-viral replication and suppression of CSS.17,18,23,33 These evidences clearly warrant further research and randomized trials of IFN and GC as a combination therapy for COVID-19.“

“ Additionally, IFN themselves have recently shown promising therapeutic potential against COVID-19 with molecular mechanisms involving both anti-viral replication and suppression of CSS.17,18,23,33 These evidences clearly warrant further research and randomized trials of IFN and GC as a combination therapy for COVID-19.“

“ Early interferon therapy was also associated with lower prevalence of prolonged viral shedding (adjusted OR 0.24, 95% CI 0.10–0.57) only among glucocorticoids users. Additionally, these associations were glucocorticoid cumulative dose- and timing-dependent. These findings reveal potential therapeutic synergy between interferons and glucocorticoids in COVID-19 that warrants further investigation.”

https://www.nature.com/articles/s41392-021-00496-5

SHA, the document is from December.

No one has any idea what the supply of SNG001 is currently. RM said there is an army of people working on it so that is all we have to go on at present.

We are due preliminary year end results RNS and this would normally provide operational highlights. Historically this has been rns'd in February/March, although last year was delayed to May for some reason.

2 x 60,000k trades gone through at 175.

Meelie, Yes your probably right. I do find this hard to stomach given they've spent billions on test and trace and nearly 2 billion on innovation LFD tests alone. I find it hard to believe cost was the underlying factor but unfortunately its all water under the bridge now. 80,000 + poor souls lost to this earth this winter and maybe SNG001 could have saved some or many of those. £160 million would have provided a treatment and some to each one of them at £2k per treatment.

Denny, they have approx 4 million shares and the discussion was around companies within their portfolio so of course the discussion was going to be about SNG.

I think the large majority of shareholders expected an EUA after the P2 results given the pandemic. With what has happened subsequently this winter it appears a mistake not to have granted it.

Thanks Jerry

Missed the Q&A. Do you think there will be a transcript or replay? Was the September PFS the main takeaway. Brilliant news and the next 6 months will be very exciting for GGP.

Genesis, That is not true. There are many trades in an auction. The UT is just the last trade in the auction period where a buyer and seller match price.

Genesis, It doesn't happen with all shares, particularly AIM shares. I have been watching Morningstar for weeks and I think it has to do with SNG being on SETS whereas many other aim stocks are traded on SEAQ. All the AIM shares in my portfolio don't have the same after market auction trades. You can see below GGP doesn't have these large amount of trades during the auction period. The links you have provided are companies traded on SETS. These trades have something to do with the pre and post market auctions. I have posted previously links that explain that these auction periods are where most of the days trading is done. Below is todays GGP Morningstar trades, a share that is traded on SEAQ and it is nothing like the SNG data.

Until we see any TR's it is all pretty irrelevant in any case as these post market trades are having no impact on the share price in subsequent sessions.

https://tools.morningstar.co.uk/uk/stockreport/default.aspx?tab=0&vw=st&SecurityToken=0P00007YUF%5D3%5D0%5DE0WWE%24%24ALL&Id=0P00007YUF&ClientFund=0&CurrencyId=BAS

Thanks AD. Good luck with your recovery.

Interesting. Hope symptoms have abated for you now AD. Were you assessed as per the protocol or was it just a general check up on how you were felling?

order filling!

https://bidstats.uk/tenders/2021/W08/745734350

"LFDs are one of the tools being used to help us to detect and fight COVID-19.
All LFDs must undergo a rigorous validation programme, which PHE Porton Down has developed in conjunction with the University of Oxford, prior to them being deployed.
We know that one in three people who have coronavirus never show any symptoms but that does not mean they are not infectious.
These devices can help identify people who have high levels of virus, who do not have symptoms and would not otherwise be coming forward for a test. We are using testing to find people who have COVID-19 and ensure both they and their recent contacts self-isolate to avoid passing the virus on to other people. This allows us to reduce the risk of local outbreaks and manage them if they do occur."

Meelie, Extavia is being trialled in a nebulised form in France. I suspect this is what the health minister was talking about as the trial has been running since July 2020.

The reference to interferon for EPIC trial is ...... "Benefit of plasma exchanges in patients presenting anti-autoantibodiesType 1 interferon with severe COVID-19 -"

You sure pmjh. Looks like plasma trial. The translation...

(1) 3 exchange sessions of 1.5 times the plasma volume per 4% albumin on D1, D3, D5 in addition to the treatmentstandard including in particular dexamethasone.
(2) Standard treatment, including Dexamethasone

Great post. Thats how I remember it!

Newcrest updates in March and April will get this back into the 30p range.